Biomedicines (Feb 2022)

Intraamygdaloid Oxytocin Reduces Anxiety in the Valproate-Induced Autism Rat Model

  • Kristóf László,
  • Orsolya Kiss,
  • Dávid Vörös,
  • Kitti Mintál,
  • Tamás Ollmann,
  • László Péczely,
  • Anita Kovács,
  • Olga Zagoracz,
  • Erika Kertes,
  • Veronika Kállai,
  • Bettina László,
  • Edina Hormay,
  • Beáta Berta,
  • Attila Tóth,
  • Zoltán Karádi,
  • László Lénárd

DOI
https://doi.org/10.3390/biomedicines10020405
Journal volume & issue
Vol. 10, no. 2
p. 405

Abstract

Read online

Background: Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder affecting about 1.5% of children, and its prevalence is increasing. Anxiety is one of the most common comorbid signs of ASD. Despite the increasing prevalence, the pathophysiology of ASD is still poorly understood, and its proper treatment has not been defined yet. In order to develop new therapeutic approaches, the valproate- (VPA) induced rodent model of autism can be an appropriate tool. Oxytocin (OT), as a prosocial hormone, may ameliorate some symptoms of ASD. Methods: In the present study, we investigated the possible anxiolytic effect of intraamygdaloid OT on VPA-treated rats using the elevated plus maze test. Results: Our results show that male Wistar rats prenatally exposed to VPA spent significantly less time in the open arms of the elevated plus maze apparatus and performed significantly less head dips from the open arms. Bilateral OT microinjection into the central nucleus of the amygdala increased the time spent in the open arms and the number of head dips and reduced the anxiety to the healthy control level. An OT receptor antagonist blocked the anxiolytic effects of OT. The antagonist by itself did not influence the time rats spent in the open arms. Conclusions: Our results show that intraamygdaloid OT has anxiolytic effects in autistic rats.

Keywords